Some With Type 2 Diabetes Inappropriately Monitoring Blood Glucose
MONDAY, Dec. 17, 2018 -- A considerable proportion of patients with type 2 diabetes may be self-monitoring blood glucose inappropriately, according to a research letter published online Dec. 10 in JAMA Internal Medicine.
Kevin D. Platt, M.D., from the University of Michigan in Ann Arbor, and colleagues performed a retrospective analysis of claims data to quantify the rate of use and cost of self-monitoring blood glucose supplies that are potentially used inappropriately, focusing on test strips. The authors followed individuals with type 2 diabetes for at least one year after filling a prescription for test strips. If no prescription was filled, they following individuals for the calendar year of 2014.
A total of 370,740 individuals with type 2 diabetes met the inclusion criteria; during the year, 23.4 percent (86,747 individuals) filled three or more claims for test strips. The researchers found that 51,820 individuals (14 percent of the study population) were deemed to be potentially using the supplies inappropriately; 32,773 and 19,047 individuals were taking agents not considered to be a risk for causing hypoglycemia and had no claims for any antidiabetic medications, respectively. These groups used a median of 2.0 strips per day. Per person, per year, the median claims cost for test strips was $325.54. The mean consumer copayment was $18.14 annually for test strips.
"Strategies to improve engagement among clinicians and to educate patients are warranted to reduce low-value care," the authors write.
One author disclosed financial ties to the pharmaceutical and health care industries.
© 2020 HealthDay. All rights reserved.
Posted: December 2018
Read this next
THURSDAY, Oct. 22, 2020 -- For patients with type 2 diabetes, consumption of green tea and coffee is associated with reduced all-cause mortality, according to a study published...
THURSDAY, Oct. 15, 2020 -- Ertugliflozin is noninferior to placebo with respect to major adverse cardiovascular events among patients with type 2 diabetes and atherosclerotic...
WEDNESDAY, Oct. 14, 2020 -- Sitagliptin treatment added to standard care is associated with reduced mortality and improved clinical outcomes for patients with type 2 diabetes...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.